Preclinical evaluation of superantigen (Staphylococcal Enterotoxin B) in the intravesical immunotherapy of superficial bladder cancer

International Journal of Cancer

Volumn 115, Issue 4, 2005, Pages 591-598

  Perabo, Frank G E ^a,c   Willert, Patricia L ^a   Wirger, Andreas ^b   Schmidt, Doris H ^a   Wardelmann, Eva ^a   Sitzia, Mario ^a   Von Ruecker, Alexander ^a   Mueller, Stefan C ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c NONE   (Germany)

Author keywords

Apoptosis; Bladder cancer; Fas ligand; Staphylococcal enterotoxin B; Superantigen

Indexed keywords

STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER MODEL; CANCER STAGING; COCULTURE; CONTROLLED STUDY; CYTOCHEMISTRY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN VITRO STUDY; NICK END LABELING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, BACTERIAL; APOPTOSIS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; ENTEROTOXINS; FEMALE; HUMANS; IMMUNOTHERAPY; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; RATS; RATS, INBRED F344; URINARY BLADDER NEOPLASMS;

EID: 18544387301     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20941     Document Type: Article

References (55)

1. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-48.
2. Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical bacillus Calmette-Guerin in Ta and Tl bladder cancer (Cochrane review). Cochrane Database Syst Rev 2000;4:CD001986.
3. Zlotta AR, Van Vooren JP, Denis O, Drowart A, Daffe M, Lefevre P, Schandene L, De Cock M, De Bruyn J, Vandenbussche P, Jurion F, Palfliet K, et al. What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer? Int J Cancer 2000;87:844-52.
4. Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-α2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J Immunol 1999;162:2399-405.
5. Patard JJ, Muscatelli-Groux B, Saint F, Popov Z, Maille P, Abbou C, Chopin D. Evaluation of local immune response after intravesical bacille Calmette-Guérin treatment for superficial bladder cancer. Br J Urol 1996;78:709-14.
6. Thanhauser A, Bohle A, Schneider B, Reiling N, Mattern T, Ernst M, Flad HD, Ulmer AJ. The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 1995;40:103-8.
7. Baker MD, Acharya KR. Superantigens: structure-function relationships. Int J Med Microbiol 2004;293:529-37.
8. Petersson K, Forsberg G, Walse B. Interplay between superantigens and immunoreceptors. Scand J Immunol 2004;59:345-55.
9. Alouf JE, Muller-Alouf H. Staphylococcal and streptococcal superantigens: molecular, biological and clinical aspects. Int J Med Microbiol 2003;292:429-40.
10. Dohlsten M, Sundstedt A, Bjorklund M, Hedlund G, Kalland T. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer 1993;54:482-8.
11. Lando PA, Hedlund G, Dohlsten M, Kalland T. Bacterial superantigens as anti-tumor agents: induction of tumour cytotoxicity in human lymphocytes by staphylococcal enterotoxin A. Cancer Immunol Immunother 1991;33:231-7.
12. Lando PA, Dohlsten M, Ohlsson L, Kalland T. Tumor-reactive superantigens suppress tumor growth in humanized SCID mice. Int J Cancer 1995;62:466-71.
13. Litton MJ, Dohlsten M, Lando PA, Kalland T, Ohlsson L, Andersson J, Andersson U. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 1996;26:1-9.
14. + T-cells during the anti-tumour effects of targeted superantigens. Br J Cancer 1999;81:359-66.
15. Herrmann T, Romero P, Sartoris S, Paiola F, Accolla RS, Maryanski JL, MacDonald HR. Staphylococcal enterotoxin-dependent lysis of MHC class II negative target cells by cytolytic T lymphocytes. J Immunol 1991;146:2504-12.
16. Ochi A, Migita K, Xu J, Siminovitch K. In vivo tumor immunotherapy by a bacterial superantigen. J Immunol 1993;151:3180-6.
17. Penna C, Dean PA, Nelson H. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases. Cancer Res 1994;54:2738-43.
18. Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S. Cooperativity of Staphylococcus aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000;60:2710-15.
19. Reid IM, Lundy JK, Donohue JH. The bispecific antibody 500A2 x 96.5 targets T-lymphocytes activated in vivo with staphylococcal enterotoxin B (SEB) against CL62 melanoma cells in vitro. Surg Oncol 1994;3:279-85.
20. Rosendahl A, Kristensson K, Carlsson M, Skartved NJ, Riesbeck K, Sogaard M, Dohlsten M. Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. Int J Cancer 1999;81:156-63.
21. Shimizu M, Yamamoto A, Nakano H, Matsuzawa A. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells. Cancer Res 1996;56:3731-6.
22. Forsberg G, Ohlsson L, Brodin T, Bjork P, Lando PA, Shaw D, Stern PL, Dohlsten M. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer 2001;85:129-36.
23. Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, Shannon B, Guedez Y, Kotb M, Vitek L, Persson R, Gunnarsson PO, Kalland T, et al. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol 1997;15:1994-2007.
24. Alpaugh RK, Schultz J, McAleer C, Giantonio BJ, Persson R, Burnite M, Nielsen SE, Vitek L, Persson B, Weiner LM. Superantigen-targeted therapy: phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies. Clin Cancer Res 1998;4:1903-14.
25. Nielsen SE, Zeuthen JL, Persson B, Alenfall J, Hansen HH. Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma. J Immunother 2000;23:146-53.
26. Kominsky SL, Torres BA, Hobeika AC, Lake FA, Johnson HM. Superantigen enhanced protection against a weak tumor-specific melanoma antigen: implications for prophylactic vaccination against cancer. Int J Cancer 2001;94:834-41.
27. Bonfoco E, Stuart PM, Brunner T, Lin T, Griffith TS, Gao Y, Nakajima H, Henkart PA, Ferguson TA, Green DR. Inducible non-lymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 1998;9:711-20.
28. Boshell M, McLeod J, Walker L, Hall N, Patel Y, Sansom D. Effects of antigen presentation on superantigen-induced apoptosis mediated by Fas/Fas ligand interactions in human T cells. Immunology 1996;87:586-92.
29. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley A, Goodwin RG, Smith CA, Ramsdell F, Lynch DH. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-7.
30. Sperber K, Bauer J, Pizzimenti A, Najfeld V, Mayer L. Identification of subpopulations of human macrophages through the generation of human macrophage hybridomas. J Immunol Methods 1990;129:31-40.
31. Steinberg GD, Brendler CB, Ichikawa T, Squire RA, Isaacs JT. Characterisation of an N-methyl-N-nitrosourea induced autochthonous rat bladder cancer model. Cancer Res 1990;50:6668-74.
32. Wirger A, Köppl H, Perabo FGE, Amann B, Grüllich CC, Felcht H. Establishment of an in vivo model of superficial transitional cell bladder cancer in rats. Aktuelle Urol 1998;29:37.
33. UICC. TNM classification of malignant tumors, 4th ed., 2nd rev. Berlin: Springer-Verlag, 1992.161-2.
34. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-80.
35. Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette-Guérin immunotherapy in 1.278 patients with bladder cancer. J Urol 1986;135:272-4.
36. Berry DL, Blumenstein BA, Magyarym DL, Lamm DL, Crawford ED. Local toxicity patterns associated with intravesical bacillus Calmette-Guérin: a Southwest Oncology Group study. Int J Urol 1995;3:98-101.
37. Hedlund G, Dohlsten M, Lando PA, Kall T. Staphylococcal enterotoxins direct and trigger CTL killing of autologous HLA-DR mononuclear leucocytes and freshly prepared leukemia cells. Cell Immunol 1990;129:426-34.
38. + cytotoxic T lymphocyte effector function by staphylococcus enterotoxin B. J Immunol 1998;161:5179-86.
39. Radsak M, Iking-Konert C, Stegmaier S, Andrassy K, Hansch GM. Polymorphonuclear neutrophils as accessory cells for T-cell activation: major histocompatibility complex class II restricted antigen-dependent induction of T-cell proliferation. Immunology 2000;101:521-30.
40. Adolphs HD, Schwabe HW, Helpap B, Volz C. Cytomorphological and histological studies on the urothelium during and after chemoimmune prophylaxis. Urol Res 1984;12:129-33.
41. de Boer EC, de Jong WH, van der Meijden AP, Steerenberg PA, Witjes F, Vegt PD, Debruyne FM, Ruitenberg EJ. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 1991;19:45-50.
42. Schuberth HJ, Krueger C, Hendricks A, Bimczok D, Leibold W. Superantigen-dependent accelerated death of bovine neutrophilic granulocytes in vitro is mediated by blood mononuclear cells. Immunobiology 2000;202:493-507.
43. Hedlund G, Dohlsten M, Petersson C, Kalland T. Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells. Cancer Immunol Immunother 1993;36:89-93.
44. Ochi A, Yuh K, Migita K, Kawabe Y. Effects of staphylococcal toxins on T-cell activity in vivo. Chem Immunol 1992;55:115-36.
45. + T cell: receptor-dependent cytolysis in the absence of interleukin-2 production. Science 1991;251:1228-31.
46. Baschieri S, Lees RK, Lussow AR, MacDonald HR. Clonal anergy to staphylococcal enterotoxin B in vivo: selective effects on T cell subsets and lymphokines. Eur J Immunol 1993;23:2661-6.
47. Roberts AI, Blumberg RS, Christ AD, Brolin RE, Ebert EC. Staphylococcal enterotoxin B induces potent cytotoxic activity by intraepithelial lymphocytes. Immunology 2000;101:185-90.
48. Avery AC, Markowitz JS, Grusby MJ, Glimcher LH, Cantor H. Activation of T cells by superantigen in class II-negative mice. J Immunol 1994;153:4853-61.
49. Lando PA, Olsson C, Kalland T, Newton D, Kotb M, Dohlsten M. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II. J Immunol 1996;157:2857-63.
50. Lamphear J, Stevens K, Rich RR. Intercellular adhesion molecule-1 and leukocyte function associated antigen 3 provide costimulation for superantigen induced T lymphocyte proliferation in the absence of a specific presenting molecule. J Immunol 1998;160:615-23.
51. LeClaire RD, Bavari S. Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality. Antimicrob Agents Chemother 2001;45:460-3.
52. Abrahmsen L. Superantigen engineering. Curr Opin Struct Biol 1995;5:464-70.
53. Hansson J, Ohlsson L, Persson R, Andersson G, Ilback NG, Litton MJ, Kalland T, Dohlsten M. Genetically engineered superantigens as tolerable antitumor agents. Proc Natl Acad Sci USA 1997;94:2489-94.
54. Newton DW, Dohlsten M, Lando PA, Kalland T, Olsson C, Kotb M. MHC class II-independent, Vβ-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma. Int J Mol Med 1998;1:157-62.
55. Erlandsson E, Andersson K, Cavallin A, Nilsson A, Larsson-Lorek U, Niss U, Sjoberg A, Wallen-Ohman M, Antonsson P, Walse B, Forsberg G. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy. J Mol Biol 2003;333:893-905.